ADC Therapeutics highlights LOTIS-7 results and cash runway
ADC Therapeutics says ZYNLONTA continues showing strong efficacy with manageable safety in DLBCL and indolent lymphomas, alongside promising LOTIS-7 results, expansion into earlier treatment lines, and a regulatory strategy adapting to FDA feedback. The company also states its financial runway extends into 2028.